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Background: We assessed the sensitivity to adjuvant chemotherapy in cell cycle checkpoint kinase 2 (CHEK2) vs non-CHEK2
breast cancer patients by comparing the contralateral breast cancer incidence and distant disease-free and breast cancer-specific
survival between both groups, stratified for adjuvant chemotherapy.
Methods: One Dutch hereditary non-BRCA1/2 breast cancer patient cohort (n¼ 1220) and two Dutch cohorts unselected for
family history (n¼ 1014 and n¼ 2488, respectively) were genotyped for CHEK2 1100delC. Hazard ratios for contralateral breast
cancer, distant disease-free and breast cancer-specific death for mutation carriers vs noncarriers were calculated using the Cox
proportional hazard method, stratified for adjuvant chemotherapy.
Results: The CHEK2 mutation carriers (n¼ 193) had an increased incidence of contralateral breast cancer (multivariate hazard ratio
3.97, 95% confidence interval 2.59–6.07). Distant disease-free and breast cancer-specific survival were similar in the first 6 years in
mutation carriers compared with noncarriers, but diverted as of 6 years after breast cancer diagnosis (multivariate hazard ratios and
95% confidence intervals 2.65 (1.79–3.93) and 2.05 (1.41–2.99), respectively). No significant interaction between CHEK2 and
adjuvant chemotherapy was observed.
Conclusions: The CHEK2 1100delC-associated breast cancer is associated with a higher contralateral breast cancer rate as well as
worse survival measures beyond 6 years after diagnosis. No differential sensitivity to adjuvant chemotherapy was observed in
CHEK2 patients.
In 2002, the cell cycle checkpoint kinase 2 (CHEK2) gene was
identified as the first moderate-risk susceptibility gene for breast
cancer. The CHEK2 1100delC mutation has been associated with a
two- to three-fold increased risk of developing breast cancer in
women (Meijers-Heijboer et al, 2002; The CHEK2-Breast Cancer
Consortium, 2002; Weischer et al, 2008; Cybulski et al, 2011). The
frequency of the CHEK2 1100delC mutation is relatively high
in the Netherlands, being B1% in the general population, 2–4%
in unselected breast cancer patients and 5–6% in breast cancer
patients with a family history of breast cancer (The CHEK2-Breast
Cancer Consortium, 2002; The CHEK2 Breast Cancer Case-
Control Consortium, 2004; Hollestelle et al, 2010).
The CHEK2 kinase acts as a tumour suppressor and plays a
critical role in DNA damage repair. Because of a compromised
DNA repair mechanism, it has been hypothesised that CHEK2
mutation carriers might have an increased sensitivity to
chemotherapeutic agents causing double-strand DNA breaks, such
as platinum or anthracyclines (Nevanlinna and Bartek, 2006).
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Previous studies showed that CHEK2 1100delC-associated
breast cancer patients had mainly oestrogen receptor (ER)-positive
tumours (de Bock et al, 2006; Nagel et al, 2012; Weischer et al,
2012), and a higher incidence of contralateral breast cancer
compared with noncarriers (de Bock et al, 2004; Schmidt et al,
2007; Weischer et al, 2012). In addition, a worse disease-free and
overall survival has been observed in CHEK2 1100delC-associated
breast cancer patients compared with patients without this
mutation (de Bock et al, 2004; Schmidt et al, 2007; Weischer
et al, 2012). In the overall breast cancer population, the risk of
contralateral breast cancer is reduced by adjuvant chemotherapy
(Bertelsen et al, 2008; Reding et al, 2010). Data on the impact of
adjuvant chemotherapy on the contralateral breast cancer risk and
survival of CHEK2 1100delC-associated breast cancer patients vs
noncarriers have not been reported yet. If CHEK2 1100delC
mutation carriers are indeed more sensitive to chemotherapy due
to a defective DNA repair mechanism, the differences in
contralateral breast cancer incidence and in distant disease-free
and breast cancer-specific survival in CHEK2 mutation carriers
compared with noncarriers would be most pronounced in breast
cancer patients not treated with adjuvant chemotherapy.
In this study we therefore evaluated the contralateral breast
cancer rate, distant disease-free survival and breast cancer-specific
survival in breast cancer patients with the CHEK2 1100delC
mutation compared with patients without this mutation, stratified
for adjuvant treatment with chemotherapy.
MATERIALS AND METHODS
Three different cohorts of women with invasive early breast cancer
were included in this study. Overall inclusion criteria were: age at
diagnosis of first breast cancer o80 years, diagnosis of first breast
cancer after 1970, no distant metastases at or within 3 months after
primary diagnosis, no proven BRCA1 or BRCA2 mutation and
follow-up data available.
The first cohort (n¼ 1220) consisted of breast cancer patients
ascertained through the Rotterdam Family Cancer Clinic. All
selected patients were tested negative for BRCA1 and BRCA2
mutations. We refer to this cohort as the ‘non-BRCA1/2’ cohort.
The second cohort (n¼ 1014, after exclusion of 64 patients
already included in the non-BRCA1/2 cohort) consisted of
patients enrolled in the ORIGO study, designed to investigate the
percentage of BRCA1/2 mutations in an unselected breast cancer
population. This study concerned a consecutive series of breast
cancer patients. Data on contralateral breast cancer rate and survival
for CHEK2 mutation carriers vs non-carriers have been previously
described (de Bock et al, 2004). We refer to this cohort as ‘ORIGO’.
The third cohort was drawn from the Rotterdam Medical
Oncology Tumour bank (RMOT) database (n¼ 2488, after
exclusion of 114 patients already included in the non-BRCA1/2
cohort and 1 patient already included in the ORIGO cohort). The
RMOT database included breast cancer patients mainly diagnosed
in the South Western region of the Netherlands from whom fresh
frozen breast tumour specimens were submitted to the Erasmus
MC for routine ER and progesterone receptor (PgR) measurement
between 1978 and 2004. We refer to this cohort as ‘RMOT’.
Part of the non-BRCA1/2 cohort (57%) and the entire ORIGO
cohort were also included in the study of Weischer et al (2012),
investigating survival and contralateral breast cancer risk in CHEK2
1100delC mutation carriers. For the current study, follow-up of the
patients in both cohorts has been updated to July 2010.
For all eligible patients of the three cohorts, data on patient and
tumour characteristics, treatment and follow-up were collected
from the medical records. The study was approved by the
Institutional Review Board.
Genotyping. DNA was isolated from peripheral blood for patients
from the non-BRCA1/2 and ORIGO cohorts and from freshly
frozen tumour tissue for patients from the RMOT cohort (The
CHEK2 Breast Cancer Case-Control Consortium, 2004; Riaz et al,
2012). The CHEK2 1100delC mutation status was determined by
either allele-specific oligonucleotide hybridisation or Taqman
genotyping as described earlier (Meijers-Heijboer et al, 2002;
Jekimovs et al, 2005). A number of samples (n¼ 783) were
analysed with both methods, showing a concordance of 100%
between the two methods.
Statistical analyses. Differences in patient and tumour character-
istics and types of treatment between CHEK2 1100delC mutation
carriers and noncarriers were compared by t-test (continuous
variables) or w2 test (categorical variables). Events of interest were
metachronous contralateral breast cancer (diagnosed 43 months
after diagnosis of the first breast cancer), distant metastases and
breast cancer-specific death. For analyses regarding metachronous
contralateral breast cancer, the non-BRCA1/2 cohort was excluded,
because this cohort probably is enriched with cases with bilateral
breast cancer cases as contralateral breast cancer is one of the
criteria for referral for genetic testing for BRCA1/2 mutations and
therefore might overestimate the contralateral breast cancer
incidence. Kaplan–Meier curves were constructed for contralateral
breast cancer rate, distant disease-free survival and breast cancer-
specific survival for CHEK2 1100delC mutation carriers and
noncarriers separately. Censoring events overall were death not
related to breast cancer, last medical contact or end of this study
(1 July 2010), and for contralateral breast cancer rate it also included
death because of breast cancer and preventive bilateral or contralateral
mastectomy. Differences in outcome between CHEK2 1100delC
mutation carriers and noncarriers were tested by the log rank test.
We calculated univariate and multivariate hazard ratios (HRs)
and 95% confidence intervals (CIs) for the above-mentioned events
for mutation carriers vs noncarriers by the Cox proportional
hazard method. Models were adjusted for patient, tumour and
Table 1. The CHEK2 1100delC status in the three different breast cancer
patient cohorts
Carriers Noncarriers
Age Total n n % n %
Non-BRCA1/2 familial
All 1220 77 6.3 1143 93.7
o40 409 23 5.6 386 94.4
40–50 474 26 5.5 448 94.5
X50 337 28 8.3 309 91.7
ORIGO (unselected for family history)
All 1014 29 2.9 985 97.1
o40 106 3 2.8 103 97.2
40–50 283 11 3.9 272 96.1
X50 625 15 2.4 610 97.6
RMOT (unselected for family history)
All 2488 87 3.5 2401 96.5
o40 236 11 4.7 225 95.3
40–50 628 22 3.5 606 96.1
X50 1624 54 3.3 1570 96.7
Total 4722 193 4.1 4529 95.9
Abbreviations: CHEK2¼ cell cycle checkpoint kinase 2; RMOT¼Rotterdam Medical
Oncology Tumour bank.
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treatment factors, including age at and year of diagnosis, cohort
(non-BRCA1/2, ORIGO, RMOT), tumour size (T1, T2, T3 or T4,
unknown), nodal status (negative, positive, unknown), hormone
receptor status (negative, positive, unknown), differentiation grade
(1, 2, 3, unknown), type of surgery (lumpectomy, mastectomy,
none or unknown), adjuvant chemotherapy (yes, no, unknown),
adjuvant hormonal therapy (yes, no, unknown) and radiotherapy
(yes, no, unknown), and the models for distant disease-free and
breast cancer-specific survival also for contralateral breast cancer
as time-dependent variable. Tumour ER and PgR analyses were
performed by ligand binding assay or enzyme-linked immunoas-
say. The cutoff for ER and PgR positivity was 10 fmolmg 1
cytosolic protein or X10% immunopositive cells. A negative
hormone receptor status was defined as negativity for both ER and
PgR, and a positive hormone receptor status as positivity for ER
and/or PgR. Hormone receptor status was considered as unknown
if information on both ER and PgR status was lacking, or in case of
negative ER and unknown PgR status.
The proportional hazard assumption was assessed by using an
extended Cox model with time-depending covariables. A likelihood
Table 2. Patient and tumour characteristics of cell cycle checkpoint kinase 2 (CHEK2) 1100delC mutation carriers and noncarriers
Carrier Noncarrier
n % n % P-value
Number of patients 193 4529
Median follow-up in years 6.8 (0.6–31.9) 7.2 (0.1–38.9)
Age at breast cancer diagnosis
Median (years) 50.0 51.4 0.003
Mean (years) 50.1 52.8
Range (years) 22.5–78.0 18.7–79.9
o40 37 19.2 714 15.8 0.14
40–50 59 30.6 1326 29.3
X50 97 50.3 2489 55.0
Year of diagnosis
o1990 58 30.1 1590 35.1 0.04
1990–2000 83 43.0 1996 44.1
42000 52 26.9 943 20.8
Synchronous contralateral breast cancer
No 189 97.9 4443 98.1 0.87
Yes 4 2.1 86 1.9
T stage
T1 95 51.9 2074 47.2 0.23
T2 72 39.3 1886 42.9
T3 11 6.0 264 6.0
T4 5 2.7 168 3.8
Unknown 10 (5.2) 137 (3.0)
N stage
Negative 105 57.1 2388 53.9 0.31
1–3 35 19.0 1096 24.7
4þ 44 23.9 949 21.4
Unknown 9 (4.7) 96 (2.1)
Differentiation grade
1 21 14.7 370 10.5 0.11
2 52 36.4 1155 32.6
3 70 49.0 2014 56.9
Unknown 50 (25.9) 990 (21.9)
Hormone receptor status
Negative 9 5.5 759 19.3 o0.001
Positive 157 94.5 3173 80.7
Unknown 30 (15.5) 597 (13.2)
HER2/neu
Negative 73 76.0 1886 80.7 0.26
Positive 23 24.0 452 19.3
Unknown 97 (50.2) 2191 (48.3)
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ratio test was used to test whether an extended model was
significantly different compared with the proportional hazard
model. The extended models for CHEK2 and tumour size were
significant for both distant metastases (P¼ 0.003 and P¼ 0.002,
respectively) and breast cancer-specific death (P¼ 0.02 and
P¼ 0.04), indicating that the hazards for distant metastases and
breast cancer-specific death by CHEK2 1100delC and tumour size
were not proportional over time. Because the survival curves for
distant disease-free and breast cancer-specific survival for CHEK2
mutation carriers and noncarriers were similar over the first 6
years, but started to diverge after 6 years (Figure 2A and D), we
chose for an extended Cox model with tumour size as time-
dependent variable and that contains a heaviside function
(Kleinbaum and Klein, 2005), together with the CHEK2 1100delC
variable, with a cutoff point of 6 years. The corresponding model
then provided two hazard ratios for CHEK2 1100delC, one for the
first 6 years and one for beyond 6 years after breast cancer diagnosis.
Analyses for contralateral breast cancer distant disease-free and
breast cancer-specific survival were stratified for adjuvant treat-
ment with chemotherapy (yes/no). Analyses for distant disease-free
survival were also stratified for type of adjuvant chemotherapy
(anthracycline-based/nonanthracycline-based) and adjuvant hor-
monal therapy (yes/no).
Interaction terms between CHEK2 1100delC mutation status
and administration of adjuvant chemotherapy (yes/no) for the
different end points were calculated. In addition, the prognostic
impact of age at diagnosis, tumour size, nodal status, ER status,
chemotherapy and hormonal therapy were analysed separately for
CHEK2 1100delC and non-CHEK2 patients.
All analyses were performed using SPSS (version 20.0; SPSS,
Inc., Chigago, IL, USA) and Stata (version 12; Stat Corporation,
College Station, TX, USA). A two-sided Po0.05 was considered as
statistically significant.
RESULTS
In total, 193 (4.1%) of the 4722 included female breast cancer
patients tested positive for the CHEK2 1100delC mutation
(Table 1). The percentage of CHEK2 1100delC mutations was
highest in the non-BRCA1/2 cohort (6.3%, n¼ 77) vs 2.9%
(n¼ 29) in the ORIGO and 3.5% (n¼ 87) in the RMOT cohort,
respectively.
Patient and tumour characteristics of the 193 CHEK2 1100delC
mutation carriers and the 4529 non-carriers are shown in Table 2.
The median follow-up time was 6.8 years for mutation carriers and
7.2 years for noncarriers. The CHEK2 1100delC-associated breast
cancer patients were significantly younger at diagnosis than the
noncarriers (median 50.0 vs 51.4 years). In addition, mutation
carriers were more often diagnosed with breast cancer after 2000
(26.9% vs 20.8%), probably reflecting the higher percentage of
CHEK2 1100delC mutation carriers in the non-BRCA1/2 cohort, as
patients in this cohort were more often diagnosed after 2000 (51%)
compared with patients from the RMOT cohort (o1%) and
ORIGO cohort (37%; data not shown in tables). Breast cancers in
mutation carriers were more often hormone receptor positive
compared with cancers in noncarriers (94.5% vs 80.7%). No
significant differences in tumour size, nodal status, differentiation
grade and her2 expression were observed between CHEK2
1100delC mutation carriers and noncarriers.
Types of treatment are shown in Table 3. Significantly less
CHEK2-associated breast cancer patients received radiotherapy
compared with the noncarriers (62.0% vs 71.3%). This observation
could not be explained by differences in surgical therapy
(lumpectomy vs mastectomy), TN stage or age at diagnosis, but
might be partly explained by differences in the year of diagnosis
between the two groups (see Table 2). Adjuvant chemotherapy was
administered to 31% of the patients, mainly consisting of
anthracycline-containing regimens, and 24% of the patients
received adjuvant endocrine therapy, mainly consisting of
tamoxifen. This was not significant different between CHEK2
mutation carriers and noncarriers.
Contralateral breast cancer risk. The incidence of metachronous
contralateral breast cancer was higher in CHEK2 1100delC
mutation carriers than in noncarriers, with a 10-year risk of
28.9% vs 8.5%, respectively (Table 4 and Figure 1). In a
multivariate analysis, the risk of contralateral breast cancer
remained higher in mutation carriers compared with noncarriers
(HR 3.97, 95% CI 2.59–6.07).
If stratified for adjuvant chemotherapy, the increased contralateral
breast cancer rate for CHEK2 1100delC-associated breast cancer
patients was observed in both the group treated with and without
chemotherapy (HR multivariate 6.95, 95% CI 3.21–15.00 and 3.15,
95% CI 1.86–5.35, respectively). Although the HR was higher for
Table 3. Types of treatment in CHEK2 1100delC mutation carriers and
noncarriers
Carrier Noncarrier
n % n % P-value
Surgical therapy
None 0 0 10 0.2 0.80
Lumpectomy 88 47.1 2087 46.4
Mastectomy 99 52.9 2405 53.4
Unknown 6 27
Adjuvant systemic therapy
None 117 63.2 2646 59.3 0.42
Only chemotherapy 32 17.3 826 18.5
Only hormonal therapy 12 6.5 441 9.9
Chemo- and hormonal therapy 24 13.0 547 12.3
Unknown 8 69
(Neo)-adjuvant chemotherapy
None 129 69.4 3089 69.0 0.41
Anthracyclines 38 20.4 838 18.7
Anthracyclines/taxanes 0 0 68 1.5
Other 16 8.6 435a 9.7
Unknown type 3 1.6 45 1.0
Unknown if treated 7 54
Adjuvant hormonal therapy
None 143 77.3 3392 76.0 0.46
LHRH/ other 6 3.2 84b 1.9
Tamoxifen 33 17.8 812 18.2
Aromatase inhibitor 1 0.5 29 0.6
Sequential tamoxifen/aromatase
inhibitor
2 1.1 120 2.7
Unknown type 0 0 27 0.6
Unknown if treated 8 65
Radiotherapy
No 73 38.0 1298 28.7 0.006
Yes 119 62.0 3220 71.3
Unknown 1 11
Abbreviations: CHEK2¼ cell cycle checkpoint kinase 2; LHRH¼ luteinising-hormone-
releasing hormone.
aFour patients received taxanes.
bFour patients were treated with radiotherapy of the ovaries or oophorectomy.
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patients treated with adjuvant chemotherapy, no significant
interaction between the CHEK2 1100delC mutation and adjuvant
chemotherapy was observed (HR for interaction 2.15; P¼ 0.10; not
shown in Tables). Stratifying for adjuvant endocrine therapy was
not possible because only 19 CHEK2 1100delC-associated breast
cancer patients were treated with hormonal therapy. No contral-
ateral breast cancers were observed in these 19 patients.
Survival. The data regarding distant disease-free survival are
shown in Table 5 and Figure 2A–C and regarding breast cancer-
specific survival in Table 5 and Figure 2D–F. The Kaplan–Meier
curves showed a nonsignificant decreased distant disease-free
(P¼ 0.06) and breast cancer-specific survival (P¼ 0.14) for
CHEK2-associated patients compared with non-CHEK2 patients
(Figure 2A and D).
As can be observed in the Kaplan–Meier curves, the distant
disease-free (Figure 2A) and breast cancer-specific survival
(Figure 2D) were similar over the first 6 years after breast cancer
diagnosis for CHEK2 1100delC mutation carriers and noncarriers
and started to diverge after 6 years. In the first 6 years after breast
cancer diagnosis, the multivariate hazard ratios for CHEK2 vs non-
CHEK2 breast cancer patients were not significant for distant
disease-free (1.08; 95% CI 0.83–1.42) and breast cancer-specific
survival (1.00, 95% CI 0.71–1.41). Survival outcomes beyond 6
years after breast cancer diagnosis, however, were significantly
worse for CHEK2 mutation carriers compared with noncarriers.
Multivariate HRs for the period beyond 6 years after breast cancer
diagnosis were 2.65 (95% CI 1.79–3.93) for distant disease-free and
2.05 (95% CI 1.41–2.99) for breast cancer-specific survival,
respectively.
If we stratified our analyses for adjuvant chemotherapy, a
significantly worse distant disease-free (P¼ 0.002) and a trend for
a worse breast cancer-specific survival (P¼ 0.05) were observed for
CHEK2-associated compared with non-CHEK2-associated breast
cancer patients in the chemotherapy group (Figure 2C and F) that
was not observed in the group not treated with chemotherapy
(P¼ 0.52 and P¼ 0.40, respectively, Figure 2B and E). However, in
both treatment groups, the group treated with and the group
treated without adjuvant chemotherapy, we observed in the first
6 years after breast cancer diagnosis no significant differences in
distant disease-free survival between CHEK2 mutation carries and
noncarriers (HR multivariate 1.41, 95% CI 0.91–2.16 and HR
multivariate 0.98, 95% CI 0.69–1.38, respectively; Table 5), whereas
beyond 6 years after breast cancer diagnosis, a significantly worse
distant disease-free survival in CHEK2 mutation carriers compared
with noncarriers was observed for both the adjuvant chemotherapy
group (HR 4.54, 95% CI 2.41–8.65) and the group without
adjuvant chemotherapy (2.31, 95% CI 1.39–3.83). Although the
HRs were higher in the adjuvant chemotherapy group compared
with the group without adjuvant chemotherapy, no significant
interaction was observed between CHEK2 1100delC and adjuvant
chemotherapy (HR interaction 1.51; P¼ 0.08; data not shown in
tables).
If analysing patients treated with anthracycline-based
chemotherapy and nonanthracycline-based chemotherapy separately,
we observed in both groups a significantly worse distant disease-free
survival beyond 6 years after breast cancer diagnosis for CHEK2
mutation carriers compared with noncarriers (HR multivariate
4.16, 95% CI 1.69–10.22 and 4.73 95% CI 1.85–12.09, respectively;
Table 5).
In addition, stratifying for treatment with hormonal therapy
(yes/no) had no major impact on the hazard ratio for disease-free
survival. The CHEK2-associated breast cancer patients had a
significantly worse distant disease-free survival than noncarriers
beyond 6 years after diagnosis, independently of treatment with
adjuvant hormonal therapy (HR 3.24, 95% CI 1.16–9.03) or
without adjuvant hormonal therapy (HR 2.88, 95% CI 1.88–4.41;
Table 5).
For breast cancer-specific survival a similar phenomenon was
observed; only beyond 6 years after breast cancer diagnosis a
significantly worse breast cancer-specific survival was observed for
CHEK2 mutation carriers vs noncarriers in both adjuvant
chemotherapy groups (i.e., the group treated with and without
adjuvant chemotherapy). In the first 6 years after breast cancer
diagnosis, we observed no significant difference in breast cancer-
specific survival between CHEK2mutation carriers and noncarriers
(Figure 2D–F and Table 5).
In Table 6, multivariate HRs with respect to breast cancer-
specific survival are presented for several prognostic factors,
separately for CHEK2 and non-CHEK2 patients. Age at diagnosis,
tumour size and nodal status appeared to be prognostic factors in
both groups, although the prognostic value of age at diagnosis was
not significant in the CHEK2 group. Interestingly, ER status
appeared only to be a prognostic factor in the non-CHEK2 group
Table 4. Rate of metachronous contralateral breast cancera
Carrier Noncarrier HR univariate HR multivariate
% (95% CI) % (95% CI) P-value HR (95% CI) HR (95% CI)
All patients
5 Years 18.3 (11.7–28.0) 3.8 (3.1–4.5) o0.001 4.07 (2.66–6.21) 3.97 (2.59–6.07)b
10 Years 28.9 (19.1–42.1) 8.5 (7.2–9.7)
No adjuvant chemotherapy
5 Years 17.7 (10.3–29.3) 4.2 (2.3–5.0) o0.001 3.18 (1.87–5.40) 3.15 (1.86–5.35)b
10 Years 24.1 (14.1–39.2) 8.8 (7.3–10.2)
Adjuvant chemotherapy
5 Years 21.9 (9.1–42.2) 2.8 (1.7–4.2) o0.001 7.35 (3.42–15.08) 6.95 (3.21–15.00)b
10 Years 42.1 (22.6–77.4) 7.4 (5.3–10.6)
Abbreviations: CHEK2¼ cell cycle checkpoint kinase 2; CI¼ confidence interval; HR¼hazard ratio.
aFor analyses regarding contralateral breast cancer (CBC), the non-BRCA1/2 cohort was excluded, because this cohort was probably enriched with patients with CBC.
bAdjusted for year of diagnosis, cohort and type of surgery. Other covariates, that is, age at diagnosis, tumour size, nodal status, hormone receptor status, differentiation grade, type of surgery,
type of chemotherapy, hormonal therapy and radiotherapy, had an impact of o10% on the HR.
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(HR 0.58, 95% CI 0.45–0.75) and not in the CHEK2 group
(HR 1.11, 95% CI 0.43–2.84). Administration of adjuvant
chemotherapy (HR 0.70 95% CI 0.35–1.41) and of adjuvant
hormonal therapy (HR 0.62, 95% CI 0.30–1.28) had a
nonsignificant favourable effect on breast cancer-specific
survival in the CHEK2 group.
DISCUSSION
In this study, we observed a worse distant disease-free and breast
cancer-specific survival for CHEK2 1100delC-associated compared
with noncarrier patients, becoming apparent beyond 6 years after
breast cancer diagnosis. Furthermore, we confirmed the higher
incidence of contralateral breast cancer in breast cancer patients
carrying the CHEK2 1100delC mutation, as observed in earlier
studies (de Bock et al, 2004; Schmidt et al, 2007; Weischer et al,
2012). Both observations were not influenced by chemotherapy,
suggesting no differential efficacy of chemotherapy in CHEK2
1100delC mutation carriers.
Interestingly, the worse distant disease-free and breast cancer-
specific survival in CHEK2 1100delC mutation carriers was only
observed beyond 6 years after breast cancer diagnosis, rather than
immediately after breast cancer diagnosis. Although earlier studies
also observed or suggested a worse (distant disease-free) survival in
CHEK2 1100delC mutation carriers (de Bock et al, 2004; Schmidt
et al, 2007; Weischer et al, 2012), none of these studies showed the
phenomenon that we observed. In view of these discordant results,
we further performed analyses in the three patient cohorts, and
found that the trend for a worse distant disease-free and breast
cancer-specific survival beyond 6 years was only observed in the
RMOT cohort, whereas in the other two cohorts the survival
became worse as of diagnosis (significant for the ORIGO cohort
and nonsignificant for the non-BRCA1/2 cohort; data not shown).
A reason for this different observation in the RMOT compared
with the non-BRCA1/2 and ORIGO cohorts might be different
patient characteristics in the RMOT cohort, such as the higher age
at diagnosis (median 55 years compared with 44 and 52 years,
respectively) and earlier diagnose years, resulting in a lower
percentage of patients treated with adjuvant chemotherapy (19% vs
52% and 37%, respectively) and adjuvant hormonal therapy (14%
vs 36% and 35%, respectively) and other types of treatment (more
often CMF and less often anthracycline-based or taxane-based
regimens). As adjuvant hormonal therapy is generally given for a
period of 5 years, it can be hypothesised that the worse survival
beyond 6 years in CHEK2-associated breast cancer patients might
be an effect of the hormonal therapy. However, evidence for this
hypothesis is not found in this study as we observed in both groups
(i.e., the group treated with and the group treated without adjuvant
hormonal therapy) a worse survival in CHEK2 mutation carriers
compared with noncarriers more than 6 years after breast cancer
diagnosis. It can also be hypothesised that the worse distant
disease-free and breast cancer-specific survival for CHEK2
mutation carriers after 6 years is caused by the higher incidence
of contralateral breast cancer in this group. However, this worse
distant disease-free and breast cancer-specific survival remained
if we censored at time of metachronous contralateral breast cancer
and/or local recurrences (data not shown) and if we included
contralateral breast cancer as time-dependent covariable in the
extended Cox models, indicating that the observed worse survival
measures are not only due to the higher incidence of contralateral
breast cancer and/or local recurrences in the CHEK2 group. As the
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Figure 1. Contralateral breast cancer rate for CHEK2-positive
(green line) and CHEK2-negative patients (blue line) in (A) all patients,
(B) patients not treated with systemic therapy and (C) patients treated
with systemic therapy. *Patients with synchronous contralateral breast
cancer and patients from the non-BRCA1/2 cohort were excluded for
this analysis regarding metachronous contralateral breast cancer.
#In (B and C), stratified for adjuvant chemotherapy, one additional
carrier and four noncarriers for whom treatment with adjuvant
chemotherapy was unknown were excluded. The full colour version of
this figure is available at British Journal of Cancer online.
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worse distant disease-free and breast cancer-specific survival cannot
be explained by a reduced sensitivity to systemic therapy and by the
higher incidence of contralateral breast cancer, we suppose that a
different tumour biology might play a role. More research is needed
into tumour biology of CHEK2 breast cancers.
The CHEK2 kinase acts as a tumour suppressor and plays a
critical role in DNA damage repair. In response to double-strand
DNA breaks, CHEK2 is activated by ataxia telangiectasia mutated
(ATM) and involved in cell cycle control, DNA repair and
apoptosis. The CHEK2 kinase phosphorylates TP53 and BRCA1,
whereupon BRCA1 represses the nonhomologous end-joining
pathway and activates the homologous recombination repair
pathway (Nevanlinna and Bartek, 2006; Tung and Silver, 2011;
Roeb et al, 2012). Based on the role of CHEK2 kinase in activating
the repair mechanism of double-strand DNA breaks and the role of
CHEK2 in the coordination of the mitotic spindle assembly, we
hypothesised that CHEK2 1100delC mutation carriers might be
more sensitive to chemotherapy. For BRCA1-associated breast
cancer patients, there is growing evidence from in vitro studies on
BRCA1-deficient cells and retrospective clinical studies on BRCA1
mutation carriers suggesting a higher sensitivity to chemother-
apeutic agents causing double-strand DNA breaks, such as
platinum or anthracyclines (Kriege et al, 2009; Bayraktar and
Gluck, 2012). However, the results found in the current study do
not support the hypothesis that CHEK2 mutation carriers have an
increased sensitivity to chemotherapy, neither for anthracycline-
based regimens nor for nonanthracycline-based regimens.
In contrast, the observations on the worse distant disease-free
and breast cancer-specific survival and the higher contralateral
breast cancer rate in CHEK2 mutation carriers being most
pronounced in the group treated with chemotherapy suggest that
CHEK2 mutation carriers are rather less than more sensitive to
chemotherapy compared with noncarrier breast cancer patients.
However, as the interaction between CHEK2 and adjuvant
chemotherapy is not significant, we cannot prove a decreased
sensitivity to adjuvant chemotherapy in CHEK2 breast cancer
patients. It might be that differences in patient and tumour
characteristics between the groups treated with and without
adjuvant chemotherapy may have influenced the results of the
analyses stratified for adjuvant chemotherapy. Patients treated with
adjuvant chemotherapy were younger at diagnosis, were more
often diagnosed after 2000 (anthracycline-based chemotherapy
being common), had a larger tumour size, had more often node
positive and hormone receptor negative tumours and were more
often treated with mastectomy and hormonal therapy than patients
not treated with adjuvant chemotherapy. It might be that especially
younger or node-positive CHEK2-associated breast cancer patients
have a worse prognosis compared with noncarriers.
The increased risk of contralateral breast cancer in CHEK2
1100delC mutation carriers was observed in patients treated
with adjuvant chemotherapy as well as in patients not receiving
adjuvant chemotherapy. A factor to take into account hereby is
radiotherapy, as it was suggested that CHEK2 mutation carriers
might be more sensitive to ionising radiation (Broeks et al, 2004,
2007; Mellemkjaer et al, 2008). However, in multivariate analyses
we found an increased risk of contralateral breast cancer in both
patients treated with (HR 4.12 95% CI 2.49–6.83) and without
radiotherapy (HR 3.17 95% CI 1.36–7.35; data not shown).
The strengths of our study include the relatively large sample
size, the known tumour and treatment data and the homogeneous
population from one country. To our knowledge, this is in fact the
largest study on survival in CHEK2 1100delC breast cancer patients
with available treatment data enabling to investigate the effect of
adjuvant chemotherapy in this data set.
We are however aware of some limitations. First, this is a
retrospective study and consequently treatment was provided on
indication, according to the Dutch guidelines existing for the
respectively treatment years. Although treatment guidelines have
changed over time, in general, patients with the worst prognosis
(based on age at diagnosis and tumour stage/characteristics) received
adjuvant chemotherapy. This probably is the reason why patients
receiving adjuvant chemotherapy had a worse distant disease-free
survival (median 6.5 and 15.0 years for CHEK2 mutation carriers
and noncarriers, respectively; Figure 2C) compared with patients not
receiving adjuvant chemotherapy (11.0 and 16.8 years for mutation
carriers and noncarriers, respectively; Figure 2B).
Another possible limitation is longevity bias in the non-BRCA1/2
group, developed by selection of preferably long-living patients
Table 5. Distant disease-free and breast cancer-specific survival
HR o6 years after diagnosis HR X6 years after diagnosis
Univariate Multivariate Univariate Multivariate
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Distant disease-free survival
All patients 1.02 (0.78–1.33) 1.08 (0.83–1.42)a 2.15 (1.45–3.18) 2.65 (1.79–3.93)a
No adjuvant chemotherapy 0.90 (0.64–1.27) 0.98 (0.69–1.38)b 1.98 (1.19–3.28) 2.31 (1.39–3.83)b
Adjuvant chemotherapy 1.38 (0.90–2.13) 1.41 (0.91–2.16)c 3.64 (1.94–6.81) 4.54 (2.41–8.56)c
Anthracycline-based chemotherapy 1.58 (0.92–2.72) 1.59 (0.92–2.75)c 3.64 (1.55–8.55) 4.16 (1.69–10.22)c
Nonanthracycline-based chemotherapy 1.23 (0.61–2.50) 1.16 (0.57–2.35)c 3.76 (1.49–9.47) 4.73 (1.85–12.09)c
No adjuvant hormonal therapy 1.01 (0.75–1.36) 1.08 (0.80–1.45)a 2.43 (1.59–3.71) 2.88 (1.88–4.41)a
Adjuvant hormonal therapy 1.22 (0.66–2.23) 1.36 (0.74–2.51)a 2.79 (1.01–7.73) 3.24 (1.16–9.03)a
Breast cancer-specific survival
All patients 0.96 (0.68–1.35) 1.00 (0.71–1.41)b 1.75 (1.20–2.54) 2.05 (1.41–2.99)b
No adjuvant chemotherapy 0.92 (0.60–1.41) 1.00 (0.65–1.53)b 1.68 (1.03–2.73) 2.03 (1.25–3.32)b
Adjuvant chemotherapy 1.10 (0.61–1.97) 1.05 (0.59–1.88)b 2.33 (1.29–4.21) 2.55 (1.40–4.64)b
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
aAdjusted for tumour size and chemotherapy, and other covariates had an impact of o10% on the HR.
bAdjusted for tumour size, and other covariates had an impact of o10% on the HR.
cAdjusted for tumour size and hormonal therapy, and other covariates had an impact of o10% on the HR.
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Figure 2. Distant disease-free survival for CHEK2-positive (green line) and CHEK2-negative patients (blue line) in (A) all patients, (B) patients not
treated with adjuvant chemotherapy and (C) patients treated with adjuvant chemotherapy, and breast cancer-specific survival for CHEK2-
positive (green line) and CHEK2-negative patients (blue line) in (D) all patients, (E) patients not treated with adjuvant chemotherapy and (F)
patients treated with adjuvant chemotherapy. *In (B, C, E and F) stratified for adjuvant chemotherapy, an additional 7 carriers and 54 noncarriers
for whom treatment with adjuvant chemotherapy was unknown were excluded.
Chemotherapy and survival in CHEK2 breast cancer patients BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.306 1011
who were tested for BRCA1/2 mutations (long) after their breast
cancer diagnosis. After stratifying for cohort, we indeed observed
the longest survival within the non-BRCA1/2 cohort. However, we
also performed left-truncated analyses, and the results were similar
as those from the initial analyses, with a worse distant disease-free
and breast cancer-specific survival beyond 6 years after diagnosis
for CHEK2 mutation carriers compared with noncarriers (data not
shown).
Finally, genetic testing for CHEK2 1100delC within the RMOT
cohort was performed on DNA isolated from tumour tissue and
not from peripheral blood. It is possible that some germline
CHEK2 1100delC mutations were missed because the mutant
CHEK2 allele was lost in the tumour instead of the wild-type allele
(Sodha et al, 2002; Kilpivaara et al, 2003). Moreover, a detected
CHEK2 1100delC mutation in the tumour might have been
acquired somatically, being different from a germline mutation.
Importantly, there were no discrepancies in DNA analyses test
results of CHEK2 status observed when comparing blood and
tumour sample test of 115 patients.
Currently, genotyping for CHEK2 is not yet performed at
genetic testing for breast cancer as it is not considered to have
clinical consequences. Moreover, implementation of CHEK2
genotyping (and especially presymptomatic testing of relatives) is
complicated by the observation that in breast cancer families the
breast cancer risk does not segregate completely with the presence
or absence of the 1100delC mutation (The CHEK2 Breast Cancer
Case-Control Consortium, 2004). However, the high incidence of
contralateral breast cancer in CHEK2 1100delC mutation carriers
found in the current study (10-year risk 24.1%) and in earlier
studies is comparable to the incidence of contralateral breast cancer
that we observed in BRCA1 and BRCA2 mutation carriers in an
earlier study (10-year risk 25% and 20%, respectively) (Brekelmans
et al, 2006) and in line with observations of other groups (10-year
risk ranging between 13 and 37%) (Haffty et al, 2002; Metcalfe
et al, 2004; Robson et al, 2005; Pierce et al, 2006; Graeser et al,
2009; van der Kolk et al, 2010). Based on this increased
contralateral breast cancer rate, affected BRCA1/2 mutation
carriers have a more intensive follow-up scheme for contralateral
breast cancer detection including MRI or can opt for a risk-
reducing contralateral mastectomy, even though it is unknown
whether such a risk-reducing contralateral mastectomy can
improve survival (Tung, 2011). In our opinion, this follow-up
regimen should also be offered to CHEK2 1100delC mutation
carriers after breast cancer diagnosis. In addition, as the population
frequency of the CHEK2 1100delC mutation in the Netherlands is
high, it may be relevant to discuss the implementation of
genotyping for CHEK2 in breast cancer patients. Moreover, genetic
testing for CHEK2 1100delC and may be other variants may also be
considered in other populations where the mutation frequency is
relevantly high such as Finland, Sweden, United Kingdom and
North America (Hollestelle et al, 2010).
In conclusion, CHEK2 1100delC mutation carriers had a
significantly higher incidence of contralateral breast cancer
compared with noncarriers that may have consequences for
follow-up strategies in clinical practice. Distant disease-free and
breast cancer-specific survival were similar over the first 6 years
after diagnosis, but became worse beyond 6 years after diagnosis
for CHEK2 1100delC mutation carriers compared with noncarrier
BC patients. No significant interaction between adjuvant che-
motherapy and a CHEK2 1100delC mutation was observed
regarding contralateral breast cancer or distant disease-free
survival.
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